What Is 21 CFR Part 11

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 21 CFR Part 19 is a U.S. FDA regulation established in 1997 that sets standards for electronic records and signatures in regulated industries, requiring validation, audit trails, and controls to ensure data integrity and authenticity.

Key Facts

21 CFR Part 11 was finalized on March 20, 1997, and became effective in August 1997
Applies to FDA-regulated industries including pharmaceuticals, biotechnology, and medical devices
Requires systems to have audit trails that retain original data entries and timestamps
Electronic signatures must be linked to individuals and verified through identity proofing
Non-compliance can result in FDA warning letters, product recalls, or import alerts

Overview

The U.S. Food and Drug Administration (FDA) issued 21 CFR Part 11 as a regulation governing the use of electronic records and electronic signatures in industries under its jurisdiction. Originally finalized on March 20, 1997, this rule ensures that digital data are as trustworthy and secure as paper-based documentation.

It applies to sectors such as pharmaceuticals, biotechnology, medical devices, and clinical research organizations. Compliance is critical for any organization submitting data to the FDA, including clinical trial results, manufacturing records, and quality control documentation.

Electronic records must be accurate, complete, and protected from unauthorized changes throughout their retention period, which can span decades for some drug applications.
Audit trails are mandatory and must capture who made a change, what was changed, and when, preserving the original entry even if later modified.
Electronic signatures are legally binding under Part 11 and must be uniquely linked to a single individual through identity verification processes.
Systems must undergo validation, meaning they are proven to consistently perform as intended, with documented evidence of reliability and accuracy.
Access controls must restrict system use to authorized personnel only, using methods such as passwords, biometrics, or two-factor authentication.

How It Works

21 CFR Part 11 outlines technical and procedural safeguards to ensure the authenticity, integrity, and confidentiality of digital information submitted to the FDA. These requirements apply to both internal systems and third-party software used in regulated processes.

System Validation: Software and systems must be formally validated to prove they consistently produce accurate results under defined conditions, documented in validation protocols and test reports.
Audit Trail: An automated, secure, and computer-generated record must track all changes to electronic records, including timestamps and user IDs, without allowing deletion.
Electronic Signatures: Must be unique to one individual, require a password or biometric confirmation, and be linked to the signed record to prevent repudiation.
Record Retention: Electronic records must be retained for the same duration as paper records—often minimum 2 years for most submissions, longer for drugs and devices.
Security Controls: Systems must implement role-based access, session timeouts, and encryption to prevent unauthorized access or tampering.
Backup and Recovery: Procedures must exist to restore electronic records in case of system failure, ensuring data availability and integrity over time.

Comparison at a Glance

Below is a comparison of 21 CFR Part 11 compliance requirements versus traditional paper-based systems:

Feature	21 CFR Part 11 (Electronic)	Paper-Based Systems
Data Integrity	Ensured via audit trails and system validation	Relies on physical custody and manual logs
Signature Verification	Requires identity proofing and secure login	Based on handwritten signature and witness
Access Control	Role-based permissions and authentication	Locked cabinets and controlled access rooms
Storage Space	Minimal; digital storage scalable	Extensive physical space required
Searchability	Instant search and retrieval capabilities	Manual file lookup; time-consuming

While paper systems are inherently less efficient, Part 11-compliant digital systems require significant upfront investment in validation and training. However, they offer long-term benefits in efficiency, data accuracy, and regulatory readiness.

Why It Matters

21 CFR Part 11 is foundational for modernizing FDA-regulated industries while maintaining rigorous data standards. As digital transformation accelerates, compliance ensures trust in electronic data used for drug approvals, clinical research, and product safety.

Pharmaceutical companies use Part 11-compliant systems to submit over 90% of new drug applications electronically through the FDA's eCTD system.
Clinical trial data collected via electronic data capture (EDC) systems must follow Part 11 to ensure regulatory acceptance.
Medical device manufacturers rely on electronic quality management systems (eQMS) that meet audit trail and signature requirements.
Non-compliant systems can lead to Form FDA 483 observations or warning letters, delaying product approvals.
Global harmonization efforts, such as with EU Annex 11, align closely with Part 11, facilitating international submissions.
Cloud-based platforms now offer validated, Part 11-compliant solutions, reducing barriers for small and mid-sized firms.

As regulatory expectations evolve, adherence to 21 CFR Part 11 remains essential for ensuring data integrity, supporting innovation, and maintaining public trust in health products.